Volume 29, Issue 1 - Visual Communications

Planting a “non-biological” seed – will this meme persist?

Author: Jennifer Bell

Abstract

Download the full article

References

1. Darwin Correspondence Project, “Letter no. 5140,” [cited 2019 Oct 17]. Available from: http://www.darwinproject.ac.uk/ letter/ DCP-LETT-5145.xml# mark- 5145.f3.
2. Survival of the fittest. Wikipedia [cited 2019 Oct 17]. Available from: https://en.wikipedia.org/wiki/Survival_ of_the_fittest.
3. Dawkins R. The Selfish Gene. Oxford: Oxford University Press; 1976.
4. Cavalli-Sforza LL. Genes, Peoples and Languages. Allen Lane: The Penguin Press; 2000.
5. Internet meme. Wikipedia [cited 2020 Jan 01]. Available from: https://en.wikipedia.org/wiki/Internet_ meme.
6. French C. Personal communication at The University of Edinburgh. 2004.
7. The IBN SINA Pharmaceutical Industry Ltd. Bactin® (ciprofloxacin USP) [cited 2019 Oct 20]. Available from: http://www.ibnsinapharma.com/products /pharma/general/by-brandname/ detail/bactin/.
8. Walsh G. Bio-pharmaceutical Benchmarks. Nat. Biotechnol. 2018;36(12):1136–45
9. The Motley Fool. What Is a Small-Molecule Drug? 2016 [cited 2020 Jan 01]. Available from: https://www.fool.com/knowledgecenter/ what-is-a-small-molecule-drug.aspx.
10. Thierauch K-H. Small Molecule Drugs. In: Schwab M. (eds) Encyclopedia of Cancer. Springer, Berlin, Heidelberg; 2011.
11. Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074–82.
12. US FDA. Non-Biological Complex Drugs – Challenges for approval standards and opportunities!! [cited 2020 Jan 01]. Available from: https://www.fda.gov/ media/125176/download.
13. Hussaarts L, Műhlebach S, Shah VP, et al. Equivalence of complex drug products: advances in and challenges for current regulatory frameworks, Ann. N. Y. Acad. Sci. 2017;1407: 39–49.
14. Karshikoff A, Nilsson L, Ladenstein R. Rigidity versus flexibility: the dilemma of understanding protein thermal stability. FEBS J. 2015;282(20):3899–917.
15. Rader R, Langer E. Top trends in the biopharmaceutical Industry and bioprocessing for 2019, 2018 [cited 2020 Jan 01]. Available from: https://www.bioprocessonline.com/doc/ top-trends-in-the-biopharmaceuticalindustry- and-bioprocessing-for-0001.
16. Radovan D. Biosimilar development – an overview. MEW. 2019;28(2):20–7.
17. European Medical Writers Association. Generics and biosimilars. Med Writ. 2019;28(2).
18. Thambavita D, Galappatthy P, Jayakody RL. Regulatory requirements for the registration of generic medicines and format of drug dossiers: procedures in Sri Lanka in comparison with selected regulatory authorities. J Pharm Policy and Pract. 2018;11:14;1–8.
19. Benet LZ. The role of BCS (Biopharmaceutics Classification System) and BDDCS (Biopharmaceutics Drug Disposition Classification System) in drug development. J Pharm Sci. 2013;102(1);34–42.
20. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3);413–20.
21. Crommelin DJA, de Vlieger JSB, Weinstein V, Műhlebach S, Shah VP, Schellekens H. Different pharmaceutical products need similar terminology. AAPS J. 2014;16(1);11–4.
22. Geigert J. Biologics are not chemical drugs. The Challenge of CMC Regulatory Compliance for Biopharmaceuticals and Other Biologics, 3rd ed. Springer New York; 2019;33–51.